In this video, Dr Deepak Bhatt presents a new sub-analysis of the REDUCE-IT trial, which looked at the efficacy and safety of icosapent ethyl in patients according to aspirin use. Before presenting the virtual poster, Dr Bhatt provides a brief reminder of the REDUCE-IT trial and then considers the implications of this analysis for primary and secondary prevention patients.
Filmed onsite at the AHA 2025 congress, leading specialists Dr Payal Kohli and Dr Deepak Bhatt explore the evolving landscape of triglyceride-lowering therapy in cardiovascular disease.
They review new REDUCE-IT sub-analysis data on icosapent ethyl efficacy by aspirin use, examine updated ESC guideline recommendations and discuss how eicosapentaenoic acid (EPA) delivers cardioprotective benefits extending beyond triglyceride reduction, through anti-inflammatory, antiplatelet and plaque-stabilising effects.
Gain expert perspectives on integrating EPA and other TG-lowering options, including fibrates, into contemporary practice for high cardiovascular-risk patients.
This programme is supported by an unrestricted educational grant from Amarin.
Educational Objective
- Gain expert perspectives on recent clinical data from the REDUCE-IT trial, featuring mechanistic insights into how eicosapentaenoic acid (EPA) derives its far-reaching cardiovascular benefits, including mechanisms beyond triglyceride lowering
Target Audience
- Cardiologists
- Cardiovascular Specialists
- Endocrinologists
- Internal Medicine
- Lipidologists
More from this programme
Part 1
The Evolving Landscape of EPA Beyond Triglyceride Lowering
In this video, Dr Payal Kohli discusses the importance of factoring in risk factors for ASCVD beyond LDL-C and in particular, the residual risk posed by elevated triglycerides and why simply treating triglycerides to target range may not be sufficient to actually lower overall risk. However, recent European guideline-focused updates, recommend that using high-dose icosapent ethyl (IPE) can reduce the risk of cardiovascular events.
Part 2
Pleiotropic Benefits of EPA in CVD
Dr Kohli continues to discuss why targeting elevated triglycerides with IPE appears to offer additional benefit through pleiotropic mechanisms, that may explain the MACE benefit over and above that achieved with fibrates.
| 1 session | |
| Pleiotropic Benefits of EPA in CVD | Watch now |
Part 3
Efficacy of Icosapent Ethyl by ASA Use: A Sub-Analysis of REDUCE-IT
In this video, Dr Deepak Bhatt presents a new sub-analysis of the REDUCE-IT trial, which looked at the efficacy and safety of icosapent ethyl in patients according to aspirin use. Before presenting the virtual poster, Dr Bhatt provides a brief reminder of the REDUCE-IT trial and then considers the implications of this analysis for primary and secondary prevention patients.
Faculty Biographies
Deepak L Bhatt
Executive Director of Interventional Cardiovascular Programs
Dr Deepak Bhatt is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School.
Dr Bhatt has more than 1,600 publications and has been listed by the Web of Science as a Highly Cited Researcher.
He is Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, and AHA’s Distinguished Scientist Award in 2019.